Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer

SAN DIEGO, Sept. 18, 2017 /PRNewswire/ -- Abide Therapeutics, a developer of innovative pharmaceuticals, announced today the appointment of Sapna Srivastava, Ph.D., to the position of Chief Financial and Strategy Officer. Dr. Srivastava brings to Abide more than 15 years of experience with a strong background in the biopharmaceutical industry and Wall Street.

"At Abide Therapeutics we are absolutely committed to discovering and developing novel serine hydrolase inhibitors that have a profound effect on improving patients' lives.  Our success to date in advancing our lead program, ABX-1431, into the clinic to treat diseases like Tourette Syndrome, neuromyelitis optica, and spasticity in multiple sclerosis validates the potential of the Abide platform and enables us to attract outstanding people, exemplified by our hiring of Dr. Sapna Srivastava," said Alan Ezekowitz, MBChB, DPhil, CEO and President of Abide Therapeutics.  "We are at an exciting time in the life cycle of Abide Therapeutics, and expanding our senior leadership team with an individual like Sapna, who possesses such a broad and relevant set of work experiences, will contribute immensely to the implementation of our strategy."

Dr. Srivastava has more than 15 years of experience as a senior executive in the biopharmaceutical industry and on Wall Street.  Most recently, Dr. Srivastava held the position of Chief Financial and Strategy Officer at Intellia Therapeutics, where she played a key role in equity financings including taking the company public, and in setting the strategic direction of the company.  Prior to that role, Dr. Srivastava spent over a decade on Wall Street as a Senior Biotechnology Analyst for Goldman Sachs, Morgan Stanley and ThinkEquity Partners, LLC. She began her career as a research associate at J.P. Morgan.  Dr. Srivastava has also served as an independent strategic advisor for biotechnology companies focused on developing therapeutics, and co-founded a neuroscience-focused biotechnology company. Dr. Srivastava earned her Ph.D. in neuroscience from the New York University School of Medicine and her B.S. in Biology from St. Xavier's College at the University of Mumbai.

"Abide is a remarkably unique combination of innovative science, world-class talent, and a company-wide shared commitment to positively impact the lives of people suffering from serious diseases. I feel privileged to be part of the team and look forward to contributing to the significant advances being made by Abide," said Dr. Srivastava.

About Abide Therapeutics

Abide Therapeutics combines an innovative discovery platform and a library of proprietary small molecules to address biological pathways with therapeutics that enhance the body's normal physiological response to disease. The platform enables Abide to quickly and efficiently identify, modify and validate small molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide's initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.

Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.

Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
[email protected]

SOURCE Abide Therapeutics

Related Links

http://www.abidetx.com